A PHASE I STUDY IN HEALTHY VOLUNTEERS TO ASSESS THE EFFECT OF CYTOCHROME3A4 (CYP3A4) INHIBITORS (DILTIAZEM AND ITRACONAZOLE) ON THE PHARMACOKINETICS (PK) OF AZD3293 AND THE EFFECTS OF AZD3293 ON THE PHARMACOKINETICS OF MIDAZOLAM, A CYTOCHROME 3A4 AND CYTOCHROME 3A5 (CYP3A4/CYP3A5) SUBSTRATE: